Rasio cepet Helius Medical (HSDT)

Helius Medical (HSDT) develops exclusive neuromodulation systems for stroke recovery, although the company is currently experiencing a liquidity shortage due to slow product adoption, which is forcing it to deplete its cash reserves. The stock's price history demonstrates a current metric of 13.65. The business relies on the supply of portable neuroplasticity stimulators to US research centers and specialized clinics to assist patients with injuries.

From a portfolio management perspective, this ratio assesses the ability of Helius Medical (HSDT) to settle short-term debts using its most liquid assets, completely excluding hard-to-realize product inventories. The current quick liquidity level of 13.65 demonstrates the company's financial stability, which is critical given the slow implementation of insurance reimbursements in the US that limit operational cash flow.